All News

A panel of experts, a patient, and her caregiver discuss her renal cell carcinoma diagnosis, the prevalent treatment options, and optimal strategies for patient education.

Findings from the phase 3 ADAM VTE trial indicate that apixaban yields lower rates of major bleeding compared with dalteparin as a thromboprophylactic treatment in patients with cancer.

Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.

Treatment with liso-cel produces low rates of severe cytokine release syndrome in relapsed/refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.

Black patients appear less likely than their White or Asian counterparts to meet hematologic lab criteria and treatment-related criteria necessary to enroll in clinical multiple myeloma trials.

Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.

The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.

Patients with relapsed or refractory multiple myeloma who have already undergone lymphodepletion are able to continue receiving treatment with CART-ddBCMA in the phase 2 IMMagine-1 trial.

The combination of venetoclax and ibrutinib may yield long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

The new drug application for imetelstat is based on findings from the phase 3 IMerge trial, in which the telomerase inhibitor outperformed placebo in the treatment of transfusion-dependent anemia.

Investigators of a retrospective study suggest that reducing myelosuppression may make chemotherapy safer and reduce the need for supportive care among those with extensive-stage small cell lung cancer.

An expert panel reviews the management of toxicities, genetic testing, and other topics in colorectal cancer.

Patients with HRR-mutant metastatic castration-resistant prostate cancer can now receive treatment with talazoparib and enzalutamide following the regimen’s approval by the FDA.

An updated analysis from the phase 3 ADAURA trial reports no significant changes in osimertinib’s safety profile in non–small cell lung cancer since the primary analysis.

Ashley E. Rosko, MD, recaps a recent panel discussion on treatment options for multiple myeloma, and discusses the disease space more generally.

Combining brentuximab vedotin with chemotherapy appears to significantly reduce the risk of death compared with chemotherapy alone among patients with advanced Hodgkin lymphoma.

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, offers a perspective on a clinical quandary published recently in the journal ONCOLOGY.

Thought leaders from various institutions offered their closing thoughts the 2023 ASCO Annual Meeting.

“We’re starting to see a lot of benefits with targeted therapies [and] immunotherapies. Unfortunately, these [benefits] remain limited to a small subset of patients across GI [gastrointestinal] [malignant tumors]. One of the biggest challenges is how to expand those benefits to the majority of patients.”

Thought leaders from various institutions offered their shameless plug the 2023 ASCO Annual Meeting.

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the optimal ways to manage short- and long-term toxicities associated with cancer.

The accepted new drug application is for Pemrydi RTU, a ready-to-use injectable that requires no reconstitution, dilution, or refrigeration.

Thought leaders from various institutions offered their take on the biggest winner that came out of the 2023 ASCO Annual Meeting.

Combining pembrolizumab with trastuzumab and chemotherapy did not raise any new safety signals among patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma in the phase 3 KEYNOTE-811 trial.